The 7 major multiple endocrine neoplasia type 2 markets reached a value of USD 1,369.6 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,988.7 Million by 2035, exhibiting a growth rate (CAGR) of 7.38% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 1,369.6 Million |
Market Forecast in 2035
|
USD 2,988.7 Million |
Market Growth Rate 2025-2035
|
7.38% |
The multiple endocrine neoplasia type 2 market has been comprehensively analyzed in IMARC's new report titled "Multiple Endocrine Neoplasia Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". MEN2 is an uncommon, inherited condition resulting from mutations of the RET proto-oncogene, which is responsible for causing endocrine tumors. It occurs in two subtypes, MEN2A and MEN2B, with MEN2A causing medullary thyroid carcinoma (MTC), pheochromocytomas, and hyperparathyroidism, whereas MEN2B is an aggressive form presenting with early-onset MTC, mucosal neuromas, and a marfanoid habitus. It mainly involves the thyroid, adrenal, and parathyroid glands, causing potentially life-threatening complications if untreated. The presentation depends on tumor location and growth but typically includes thyroid nodules, neck swelling, hypertension from pheochromocytoma, hyperhidrosis, palpitations, hypercalcemia, and neuromuscular disturbances. Diagnosis is dependent upon genetic evaluation for RET mutation, serum calcitonin concentrations, plasma metanephrines, and imaging methods such as ultrasound, CT, MRI, and nuclear scanning to determine the presence of tumors and extent of metastasis. Detection with early diagnosis using genetic screening for prophylactic thyroidectomy drastically improves patient results and eliminates dangers to mortality.
The increasing incidence of Multiple Endocrine Neoplasia Type 2 (MEN2), caused by inherited genetic mutations in the RET proto-oncogene, is a key driver of market expansion. As MEN2 is an autosomal dominant condition, family history carriers have a high likelihood of developing the disease, for which early genetic testing and prophylactic treatments are required. Growing recognition of predictive genetic testing has contributed to a boom in early diagnoses, allowing for timely prophylactic thyroidectomy, especially in high-risk RET mutation children. Increased use of targeted therapies like selective RET inhibitors pralsetinib and selpercatinib has also radically shifted the treatment landscape by providing improved and less toxic options compared to conventional chemotherapy. The progression in radioactive imaging and precision medicine is also stimulating market growth through the ability to detect tumors with greater accuracy and tailored treatment schemes. Additionally, clinical trials currently underway for emerging therapies against RET mutations and combination therapies are expected to further propel the market. The transition toward personalized medicine, enhanced screening campaigns, and emerging therapeutic strategies are expected to propel market growth through the forecast period.
IMARC Group's new report provides an exhaustive analysis of the multiple endocrine neoplasia type 2 market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for multiple endocrine neoplasia type 2 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple endocrine neoplasia type 2 market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current multiple endocrine neoplasia type 2 marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Market Insights
Epidemiology Insights
Multiple Endocrine Neoplasia Type 2: Current Treatment Scenario, Marketed Drugs and Emerging Therapies